EW Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally...

Stats
Šios dienos apimtis	4.96M
Vidutinė apimtis	4.02M
Rinkos kapitalizacija	51.97B
EPS	$0 ( 2024-04-25 )
Kita pelno data	( $0.700 ) 2024-07-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	37.58
ATR14	$0.101 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Lippis Daniel J.	Buy	857	Common Stock
2024-04-09	Lippis Daniel J.	Sell	857	Common Stock
2024-04-09	Lippis Daniel J.	Sell	857	Employee Stock Option (Right to Acquire)
2024-04-08	Lemercier Jean-luc M	Buy	14 400	Common Stock
2024-04-08	Lemercier Jean-luc M	Sell	107	Common Stock

INSIDER POWER
-32.00
Last 99 transactions
Buy: 337 983 \| Sell: 687 280

Tūris Koreliacija

Ilgas: 0.60 (weak)

Trumpas: -0.79 (moderate negative)

Signal:(48.119) Neutral

Edwards Lifesciences Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CVII	0.829
ERJ	0.822
PNTM	0.82
CXAC	0.814
GIA	0.811
YSAC	0.808
KOF	0.805
IBDO	0.805
ULST	0.805
IRRX	0.804

10 Labiausiai neigiamai susiję koreliacijos
NXQ	-0.842
NIC	-0.826
DBMF	-0.821
EQNR	-0.814
HBB	-0.814
CVS	-0.813
EVA	-0.806
FUL	-0.801
LDOS	-0.801

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Edwards Lifesciences Corp Koreliacija - Valiuta/Žaliavos

0.55
( weak )

0.66
( moderate )

0.00
( neutral )

0.58
( weak )

0.20
( neutral )

0.17
( neutral )

Edwards Lifesciences Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$6.00B
Bruto pelnas:	$4.63B (77.02 %)
EPS:	$2.31

FY	2023
Pajamos:	$6.00B
Bruto pelnas:	$4.63B (77.02 %)
EPS:	$2.31

FY	2022
Pajamos:	$5.38B
Bruto pelnas:	$4.30B (79.93 %)
EPS:	$2.46

FY	2021
Pajamos:	$5.23B
Bruto pelnas:	$3.98B (76.13 %)
EPS:	$2.41

Financial Reports:

No articles found.

Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.